Why the study?
The effects of complete revascularization on long-term treatment outcomes in patients over 80 years of age with ACS and multivessel coronary artery disease have not been sufficiently investigated.
Does complete revascularization reduce major adverse cardiac events in patients over 80 years of age with acute coronary syndrome and multivessel coronary artery disease?
Does complete revascularization reduce major adverse cardiac events in patients over 80 years of age with acute coronary syndrome and multivessel coronary artery disease?
Complete revascularization in octogenarians with ACS and multivessel disease reduces MACE at 1 year without increasing periprocedural complications.
BACKGROUND: The effects of complete revascularization (CR) on long-term treatment outcomes in patients over 80 years of age with acute coronary syndrome (ACS) and multivessel coronary artery disease (MVD) have not been sufficiently investigated. METHODS: In this study, we analyzed data obtained in 305 patients over 80 years of age with MVD who were admitted in the period from January 2014 to August 2017 for ACS. The patients were divided into two groups. CR was performed in 131 patients, and 174 subjects had an intervention on the symptomatic artery only [incomplete revascularization (ICR)]. The primary endpoint was one-year occurrence of the major adverse cardiac events (MACE) including death, non-fatal myocardial infarction, stroke. We also recorded cases of repeat coronary artery intervention, major bleeding events, contrast-induced nephropathy and stent thrombosis that occurred within a period of 1 year. RESULTS: The MACE rate in patients undergoing CR was significantly lower during the 12-month observation period. No statistically significant differences were observed in the rates of repeat coronary artery intervention, bleeding events, contrast-induced nephropathy, and stent thrombosis. CONCLUSIONS: CR performed in patients over 80 years of age with ACS due to MVD decreases the incidence of MACE without increasing the risk of periprocedural complications.
No takes yet. Share an insight, caveat, or question.
Berezhnoi et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: